The Journal of Steroid Biochemistry and Molecular Biology
Estrone and progesterone inhibit the growth of murine MC38 colon cancer line
Introduction
In the developed countries colorectal cancer is one of the most common cancers [1]. Chemotherapy is an important part of treatment in this neoplasm, because approximately 30% of all patients with colon cancer have metastatic disease at diagnosis, and 50% of early-stage patients will eventually develop metastatic or advanced disease [2]. For about 50 years, fluorouracil (FU) has remained the main chemotherapeutic agent in this cancer. Unfortunately, the response to FU is observed only in 10–15% patients [3]. Its combination with leucovorin (LV) enhanced the mean response ratio to 23% and became the standard regimen in adjuvant and palliative chemotherapy of this disease [4]. During the last decade FDA (Food and Drug Administration) has approved six new drugs for treatment of advanced stages of colon cancer. Three of them belong to cytotoxic agents: irinotecan (1996), oxaliplatin (2002), oral formulation of fluorouracil – capecitabine (1998), and the other three to monoclonal antibodies: bevacizumab targeting vascular endothelial growth factor (2004), cetuximab (2004) [5] and panitumumab (2006) [6], both directed against the epithelial growth factor receptor. Although the new drugs prolonged the median survival from 12 months (FU + LV) to about 21 months, the effectiveness of the therapy is still unsatisfactory and the treatment of metastatic disease remains palliative [5]. Therefore, there are still researches carried on for new substances enhacing the antineoplastic effect of FU, including cytostatic drugs as well as other biomodulators.
The role of estrogens in colon carcinogenesis has been discussed for many years. This association was suggested by some epidemiological data such as an age-specific occurrance of colorectal cancer in women [7], protective influence of increasing parity and sex differences in site specific incidences of the neoplastic lesion in bowels [8]. Moreover, a lot of observational studies [9] and the last randomized primary prevention trial – the Women's Health Initiative (WHI) [10] showed a decreased risk of colorectal cancer among menopausal women receiving hormonal replacement therapy (HRT). Although generally most of these protective effects are attributed to the action of estrogens, it could not be excluded that the positive effects are connected also with the other female sex hormone – progesterone. Such a hypothesis could be supported by the fact that in the WHI study the reduction in colon cancer risk was observed only in users of combined estrogen and progestin HRT [10], whereas in women after hysterectomy, receiving only estrogens, the protective effect was not noticed [11].
In spite of many facts implying involvement of female sex steroids in colorectal carcinogenesis, the number of studies examining the direct effect of these hormones on the colon cancer growth is limited and gives often opposing results. Studies in vitro [12] and experiments with ovariectomized animals [13], [14] have shown that estradiol (E2), which is the most often examined estrogen, can inhibit as well as stimulate the growth of this neoplasm. The influence of the weaker estrogen – estrone (E1) and progesterone on the colon cancer growth has been hardly ever a matter of study.
Thus, the aim of this paper was to examine the direct effects of estrone and progesterone applied alone or together with FU on the murine MC38 colon cancer growth in vitro assessed by two colorimetric methods reflecting changes in proliferation and apoptosis.
Section snippets
Materials and methods
Murine Colon 38 cancer cells were used in the study. The cells were routinely grown in a humidified incubator at 37 °C with 5% CO2 in RPMI 1640 medium (Sigma), supplemented with: 25 nM Hepes buffer (Sigma), 4 mM L-glutamine (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin solution (Sigma), 2 g/l sodium bicarbonate (Sigma) and 5% fetal calf serum (FCS, Biochrom). The cells were passaged every 7 days with 0.05% trypsin/0.02% EDTA (Trypsin-EDTA, Sigma) and the medium was changed every 3–4 days.
Results
Estrone in a wide range of concentrations (10−12 to 10−4 M) induced similar, moderately strong inhibition of the MC38 cancer growth, which was slightly more potent after 72 h (up to 72% of control group) than after 24 h incubation (up to 81% of control group) (Fig. 1). The inhibitory effect of estrone was not observed only for the concentration of 10−6 M in 24 h culture and for the concentration of 10−5 M in 72 h culture (Fig. 1). The beginning of action was noticed as early as after 4 h incubation in
Discussion
In the present study we have shown that estrone and progesterone inhibited MC38 colon cancer growth. To our knowledge, we have also revealed for the first time that estrone can potentiate the cytotoxic action of FU. In our study, estrone induced MC38 growth inhibition in a wide range of concentrations (10−12–10−4 M) with the exception of 10−6 M in 24 h culture and 10−5 M in 72 h culture. Such an effect could be connected with a different mechanism of action for the lower (i.e. under the ineffective
Conclusions
Summing up, we have shown in this paper that estrone and progesterone inhibited MC38 colon cancer growth and that estrone intensified cytotoxic effect of FU. Our results indicate that female sex steroids are involved in modulation of colon cancer growth. It suggests the potential use of these hormones, especially estrone, in colon cancer therapy, which could enhance the efficacy of FU. Further studies are needed to elucidate whether this hypothesis is true in human colon cancer and whether it
References (26)
- et al.
Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis
Am. J. Med.
(1999) - et al.
Functional estrogen receptor beta in colon cancer cells
Biochem. Biophys. Res. Commun.
(1999) - et al.
Estradiol is trophic for colon cancer in mice: effect on ornithine decarboxylase and c-myc messenger RNA
Gastroenterology
(1992) - et al.
Estrogen metabolism in human colorectal cancer cells
J. Steroid. Biochem. Mol. Biol.
(2002) - et al.
Dietary soy isoflavones and estrone protect ovariectomized ERalphaKO and wild-type mice from carcinogen-induced colon cancer
J. Nutr.
(2004) - et al.
Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system
Cancer Lett.
(2000) - et al.
Global cancer statistics 2002
C. A. Cancer J. Clin.
(2005) - et al.
Metastatic colorectal cancer: systemic treatment in the new millennium
Cancer Control.
(2003) - et al.
5-Fluorouracil: mechanisms of action and clinical strategies
Nat. Rev. Cancer
(2003) - et al.
Colorectal cancer
Acta Oncol.
(2003)
The price tag on progress-chemotherapy for colorectal cancer
N. Engl. J. Med.
FDA drug approval summary: panitumumab (Vectibix)
Oncologist
Reproductive factors and colon cancers
Br. J. Cancer
Cited by (13)
Role of estrone on the regulation of osteoblastogenesis
2019, Molecular and Cellular EndocrinologyCitation Excerpt :Estrone represents a physiological estrogen categorized previously as a weak estrogen. Nevertheless, in the last decades, several biochemical actions of E1, either in classical and non classical estrogen target tissue (pituitary, breast, vascular, colon) have been described (Massheimer et al., 2006; Watson et al., 2008; Motylewska and Mełeń-Mucha, 2009). This estrogen is synthesized by the catalytic activity of Cytochrome P450 enzyme aromatase through the conversion of androstenedione to estrone.
Steroid hormones are novel nucleoside transport inhibitors by competition with nucleosides for their transporters
2014, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Furthermore, steroid-dependent inhibition of nucleoside transport may affect experimental or clinical results in other studies. Several non-specific steroidal effects, which are not fully understood, such as immunosuppressible effect of overdose steroids [17], anti-tumor effect of high-dose estrogen to breast cancer [18] or colon cancer [19], may be mediated by steroid hormone-induced inhibition of nucleoside transport. Apart from pharmacological action of steroids, specific tissues, such as testis, ovary, adrenal gland, and brain are capable of the de novo synthesis of steroid hormones, and extremely high concentration of these hormones, which can be achieved in the local area can affect local availability of nucleoside [20–22].
Synthesis and cytotoxic activities of estrone and estradiol cis-dichloroplatinum(II) complexes
2012, Bioorganic and Medicinal ChemistryCitation Excerpt :This fact sparked an interest in the preparation and structure–activity relationship studies of new cytotoxic estrogen derivatives. Furthermore, over the last few decades many anticancer estrogen derivatives have been synthesized23–30 while utilizing two potential anticancer units—platinum and estrogens. Many steroidal platinum complexes have been prepared up to now.31–41
Modulation of ghrelin axis influences the growth of colonic and prostatic cancer cells in vitro
2012, Pharmacological ReportsCitation Excerpt :The superiority of non-cytotoxic targeting strategies over traditional chemotherapy is widely discussed nowadays and seems to be a promising option for the therapy of advanced stages for several cancers. Although colorectal cancer does not belong to hormone- dependent neoplasms, experimental evidence shows that its growth is modified via several hormones or hormone receptor modulators such as gastrin and its analogs, gastrin/cholecystokinin receptor (CCK-A and CCK-B) antagonist [25, 26, 37], somatostatin and its analogs [28, 29], melatonin [29], estrogens and selective estrogen receptor modulators [25, 26, 31, 32] or GHRH antagonists [39]. Moreover, some of these substances enhanced even the cytotoxic effect of FU on colon cancer growth [25, 26, 28, 31].
Cellular and molecular actions displayed by estrone on vascular endothelium
2011, Molecular and Cellular EndocrinologyCitation Excerpt :Estrone (E1) is a physiological estrogen previously categorized as weak estrogen. However, in the last few years, several biochemical actions of E1, either in classical and non classical estrogen target tissue (pituitary, breast, vascular, colon) have been described (Watson et al., 2008; Motylewska and Melén-Mucha, 2009). Although estradiol (E2) is the endogenous estrogen most often associated with female reproduction and with postmenopausal alterations and diseases, other physiological estrogens such as estrone or estriol also seem to be relevant during specific life phases, eliciting significant effects on tissue development, function and diseases.
Preclinical Evidence of Progesterone as a New Pharmacological Strategy in Human Adrenocortical Carcinoma Cell Lines
2023, International Journal of Molecular Sciences